New Canine SNAP® 4Dx® Diagnostic Test Available [Trade]
IDEXX introduces the only in-house test that allows veterinarians to simultaneously screen canine patients for heartworm and three tick-borne diseases

Westbrook, Maine, January 19, 2007—IDEXX Laboratories, Inc. (NASDAQ:IDXX), announces the availability of the new SNAP® 4Dx® test kit, an in-clinic diagnostic test that simultaneously screens dogs for four vector-borne diseases—heartworm disease, canine ehrlichiosis (Ehrlichia canis), Lyme disease and canine anaplasmosis (Anaplasma phagocytophilum, formerly Ehrlichia equi)—in approximately eight minutes. The SNAP 4Dx test is the only point-of-care test for canine anaplasmosis, an emerging health threat, Lyme borreliosis and canine ehrlichiosis.

By combining Lyme disease, ehrlichiosis and anaplasmosis with heartworm screening, SNAP 4Dx allows veterinarians to efficiently and economically screen for four diseases that are difficult to diagnose on the basis of clinical signs alone. Because the most common signs of anaplasmosis are often hidden, SNAP 4Dx is recommended for the annual screening of all dogs. The test can detect antibodies as early as eight days after the animal is infected, enabling veterinarians to treat many patients before they even get sick.

Affordable and precise, the 4Dx test delivers results with at least 98% specificity on all four diseases. “This is the only in-house test that lets veterinarians screen for heartworm and three tick-borne diseases at once, including anaplasmosis,” said Canine Rapid Assay Marketing Director Mike Sullivan. “That’s important because Lyme disease and anaplasmosis are spreading, and many dogs have both at the same time.” According to the National Center for Infectious Diseases, anaplasmosis can be transmitted not only to dogs, cats, and horses but to humans as well.

Reports of heartworm, Lyme and other tick-borne diseases are increasing in number and range. Once limited to the Mississippi River Valley and southeastern United States, heartworm infection has been found in dogs native to all 50 states. Lyme disease cases, once predominantly found in the northeastern United States, are now reported across the country. Additionally, veterinarians are now finding Lyme borreliosis and anaplasmosis co-infection, which increases the risk of disease.

IDEXX is the leader in the market for in-clinic heartworm diagnostics and is the only company that provides combination tests, such as the SNAP 4Dx test, that test simultaneously for heartworm and other health conditions at the pet-side. The SNAP 4Dx test represents another step forward in the detection of vector-borne diseases that can help veterinarians provide the best available health care for their canine patients.

For more information or to place an order, practitioners can contact their authorized IDEXX distributor, call IDEXX at 1-800-248-2483, contact their authorized IDEXX distributor or visit www.idexx.com/4dx.

About IDEXX Laboratories
IDEXX Laboratories, Inc. is a leader in companion animal health, serving practicing veterinarians around the world with innovative, technology-based offerings, including a broad range of diagnostic products and services, practice-management systems, and therapeutics. Our products enhance the ability of veterinarians to provide advanced medical care and to build more economically successful practices. IDEXX is also a worldwide leader in providing diagnostic tests and information for the production animal industry and tests for the quality and safety of water and milk. Headquartered in Westbrook, Maine, IDEXX Laboratories employs more than 3,500 people and offers products to customers in over 100 countries.

Note Regarding Forward-Looking Statements
This press release contains statements about the Company’s business prospects that are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's expectations of future events as of the date of this press release, and the Company assumes no obligation to update any forward-looking statements as a result of new information or future events or developments. Actual results could differ materially from management’s expectations. Factors that could cause or contribute to such differences include the following: the Company’s ability to develop, manufacture, introduce and market new products and enhancements to existing products; the effectiveness of the Company’s sales and marketing activities; the Company’s ability to develop, license or obtain rights to new technologies; the Company’s ability to identify acquisition opportunities, complete acquisitions and integrate acquired businesses; the impact of competition and technological change on the markets for the Company’s products; the effect of government regulation on the Company’s business, including government decisions about whether and when to approve the Company’s products and decisions regarding labeling, manufacturing and marketing products; the impact of distributor purchasing decisions on sales of our products that are sold through distribution; changes or trends in veterinary medicine that affect the rate of use of the Company’s products and services by veterinarians; the Company’s ability to obtain patent and other intellectual property protection for its products, successfully enforce its intellectual property rights and defend itself against third party claims against the Company; disruptions, shortages or pricing changes that affect the Company’s purchases of products and materials from third parties, including from sole source suppliers; the effects of government regulatory decisions, customer demand, pricing and other factors on the realizability of the Company’s inventories; the Company’s ability to manufacture complex biologic products; the effects of operations outside the U.S., including from currency fluctuations, different regulatory, political and economic conditions, and different market conditions; and the loss of key employees. A further description of these and other factors can be found in the Company's Annual Report on Form 10-K for the year ended December 31, 2005 (1.5 MB), and on the Quarterly Report on Form 10-Q for the quarter ended September 30, 2006 (520 KB), in the section captioned "Management's Discussion and Analysis of Financial Condition and Results of Operations."

This symbol indicates PDF-formatted materials. To view, you may need to download a free copy of Adobe^® Reader^® software.